The Filing Desk

Emergent BioSolutions vs Telix Pharmaceuticals

Emergent BioSolutions EBS · Telix Pharmaceuticals TLX · Pharmaceuticals

Telix Pharmaceuticals reported revenue of $804 million in fiscal 2025, about the same as Emergent BioSolutions' $743 million in fiscal 2025. Emergent BioSolutions' revenue fell 28.8% in its latest year, and Telix Pharmaceuticals' grew 55.6%. Emergent BioSolutions had an operating margin of 13.5%, against 3.7% at Telix Pharmaceuticals. Free cash flow was $157 million at Emergent BioSolutions and −$43 million at Telix Pharmaceuticals.

Side by side

Emergent BioSolutionsTelix Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$743M$804M
Revenue growth−28.8%55.6%
Revenue growth a year, last 5 years−14.0%—
Gross margin56.1%53.0%
Operating margin13.5%3.7%
Net margin7.1%−0.9%
Free cash flow$157M−$43M
Free cash flow margin21.1%−5.3%
Return on capital6.4%5.0%
Net debt to EBITDA2.0x5.1x
Dividends and buybacks$25M$0M
Change in diluted share count7.0%−2.1%
Last close$5.15$8.71
P/E at the last close——
Insider trades, last 12 monthssold $840,301bought $1.0 million, sold $0
Piotroski F-score7 of 92 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Emergent BioSolutionsTelix Pharmaceuticals
Operating margin
Percent of revenue
Emergent BioSolutionsTelix Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Emergent BioSolutionsTelix Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Emergent BioSolutions and Telix Pharmaceuticals pages.